The analgesia produced by tricyclic antidepressants (TCAs) in rats and the role of serotonin in this analgesia have been investigated in this study. Rats received intraperitoneal injections of imipramine and amitriptyline, which are TCAs, and the serotonin synthesis inhibitor, pCPA. An acute analgesic effect was measured 90 min after the first injections; a chronic effect was measured 24 h after the last injections, on the 7th and 15th days using the hot-plate method. Both antidepressants elevated the pain threshold acutely, while pretreatment with pCPA largely blocked the analgesia. Based on these data it was found that in the acute case both of the antidepressants potentiate an endogenous analgesia mechanism, which acts on the serotonergic system. After long-term use, amitriptyline, which acts on serotonin, had an analgesic effect and this effect was blocked by pCPA. Imipramine, which acts on noradrenaline, had no effect on the pain threshold in chronic use. Consequently, serotonin is an important link in TCA analgesia; noradrenaline has no effect.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/0006-8993(90)90948-b | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
An Exploration of the Interplay Between Caffeine and Antidepressants Through the Lens of Pharmacokinetics and Pharmacodynamics.
Eur J Drug Metab Pharmacokinet
January 2025
Discipline of Pharmacy, Graduate School of Health, University of Technology Sydney, Ultimo, NSW, 2007, Australia.
Caffeine consumption is regarded as a widespread phenomenon, and its usage has continued to increase. In addition, the growing usage of antidepressants worldwide and increase in mental health disorders were shown in recent statistical analyses conducted by the World Health Organisation. The coadministration of caffeine and antidepressants remains a concern due to potential interactions that can alter a patient's response to therapy.
View Article and Find Full Text PDFPatterns of self-harm presentations at a Tertiary Urban Hospital in Kenya: A retrospective 5-year study (2018-2022).
PLoS One
January 2025
Brain and Mind Institute, Aga Khan University, Nairobi, Kenya.
Introduction: Self-harm represents a complex and multifaceted public health issue of global significance, exerting profound effects on individuals and communities alike. It involves intentional self-poisoning or self-injury with or without the motivation to die. Although self-harm is highly prevalent, limited research has focused on the patterns and trends of self-harm among hospital populations in low- and middle-income countries, particularly within Africa.
View Article and Find Full Text PDFThe risks of adverse events with mirtazapine for adults with major depressive disorder: a systematic review with meta-analysis and trial sequential analysis.
BMC Psychiatry
January 2025
Copenhagen Trial Unit, Centre for Clinical Intervention Research, The Capital Region, Copenhagen University Hospital - Rigshospitalet, Blegdamsvej 9, Copenhagen Ø, DK-2100, Denmark.
Background: Mirtazapine is used to treat depression worldwide, and the effects of mirtazapine on depression rating scales are well-known. Our primary objective was to assess the risks of adverse events with mirtazapine for major depressive disorder.
Methods: We searched relevant sources from inception to 7 March 2024 for randomised clinical trials comparing mirtazapine versus placebo in adults with major depressive disorder.
Do individuals with inflammatory arthritis receive minimally adequate treatment for incident depression and anxiety: A population-based study.
Arthritis Res Ther
January 2025
Faculty of Pharmaceutical Sciences, University of British Columbia, 2405 Wesbrook Mall, Vancouver, BC, V6T 1Z3, Canada.
Objectives: Describe patterns of pharmacotherapy and psychological treatment and evaluate receipt of minimally adequate treatment for incident depression and anxiety in individuals with inflammatory arthritis (IA).
Methods: We used population-based linked administrative health databases from British Columbia, Canada to evaluate pharmacotherapy and psychological treatments for incident depression and/or anxiety among individuals with IA and without IA ('IA-free controls'). We defined minimally adequate pharmacotherapy as antidepressant prescriptions filled with ≥ 84 days' supply and adequate psychological treatment as ≥ 4 counselling/psychotherapy services.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!